Inhibition of Transketolase Improves the Prognosis of Colorectal Cancer

Linhao Zhang, Zhiyin Huang, Qiuyu Cai, Chong Zhao, Yang Xiao, Xin Quan, Chengwei Tang, Jinhang GaoFrontiers in Medicine 2022 · DOI

TL;DR

This study identifies Transketolase (TKT) as a key enzyme overexpressed in colorectal cancer (CRC) that is associated with poor patient prognosis. Inhibiting TKT in CRC cells reduced their viability, proliferation, and migration, suggesting TKT could be a novel therapeutic target and prognostic biomarker for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a significant global health challenge, ranking high in incidence and mortality. While current treatments exist, limitations like drug resistance and metastasis necessitate the discovery of new therapeutic targets and reliable prognostic biomarkers. Previous research hinted at Transketolase (TKT), an enzyme in the Pentose Phosphate Pathway (PPP), being involved in various cancers, but its specific role and prognostic significance in CRC remained unclear. This paper aims to fill that knowledge gap by investigating TKT's expression, its correlation with CRC prognosis, and the potential therapeutic benefits of inhibiting it.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They analyzed publicly available gene expression datasets (from the Gene Expression Omnibus - GEO database) to identify differentially expressed genes (DEGs) in CRC compared to normal tissues. They then used tools like GEPIA and TIMER2.0 to assess TKT's expression levels and its association with patient survival.
  • Tissue Microarray (TMA) and Immunohistochemistry (IHC): Human colon adenocarcinoma tissues and adjacent normal tissues were examined using TMA and IHC staining to visualize and quantify TKT protein expression.
  • In Vivo Xenograft Models: Human colon cancer cell lines (HCT116 and RKO) were implanted into nude mice to create xenograft tumors, which were then analyzed for TKT expression.
  • In Vitro Cell Assays:
    • Cell Viability (CCK8 Assay): Assessed the effect of TKT inhibition (using a chemical inhibitor N3PT and siRNA) on cancer cell survival.
  • Cell Proliferation (Ki-67 Immunofluorescence): Measured the impact of TKT inhibition on cell division.
  • Cell Apoptosis (Annexin V/PI Staining): Evaluated whether TKT inhibition induced programmed cell death.
  • Cell Migration (Wound-Healing and Transwell Assays): Determined the effect of TKT inhibition on the ability of cancer cells to move.
  • Western Blot: Analyzed the protein levels of key molecules in the Notch signaling pathway (NICD and Hes1) after TKT inhibition.

Datasets

The study utilized publicly available gene expression datasets from the Gene Expression Omnibus (GEO) database: GSE8671, GSE32323, GSE24514, and GSE14333. They also used data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects via the GEPIA web server. For mutation analysis, the TIMER2.0 database was used, and for TKT-associated genes, the LinkedOmics database was employed.

Key Insights and Ideas

  • TKT as a Prognostic Indicator: The most striking finding is the strong correlation between high TKT expression and poor prognosis in CRC patients. This suggests TKT could be a valuable tool for predicting patient outcomes.
  • TKT's Role in Cancer Progression: The study provides evidence that TKT actively promotes CRC progression by enhancing cell viability, proliferation, and migration, while suppressing apoptosis.
  • The Notch Signaling Connection: A crucial mechanistic insight is the link between TKT and the Notch signaling pathway. Inhibiting TKT appears to downregulate key components of this pathway (NICD and Hes1), which is known to be involved in cancer metastasis. This suggests TKT might promote CRC malignancy, at least in part, by activating Notch signaling.
  • TKT as a Therapeutic Target: The in vitro and in vivo data strongly support the idea that inhibiting TKT can suppress CRC growth and progression, making it a promising candidate for novel therapeutic strategies.

Key Results

  • TKT Overexpression: TKT was found to be significantly upregulated in colon adenocarcinoma tissues compared to normal tissues, both in patient samples and in xenograft models.
  • Prognostic Significance: High TKT expression was significantly associated with advanced TNM stages, positive lymph nodes, and poorer 5- and 10-year overall survival rates in CRC patients.
  • Inhibition Effects:
    • Inhibiting TKT (with N3PT or siRNA) significantly reduced CRC cell viability and proliferation.
  • TKT inhibition also suppressed cell migration in wound-healing and Transwell assays.
  • While N3PT treatment showed no significant effect on apoptosis, TKT siRNA transfection significantly increased apoptosis in HCT116 cells.
  • Inhibition of TKT led to decreased protein levels of NICD and Hes1, key components of the Notch signaling pathway.

Limitations and Future Work

  • In Vitro vs. In Vivo: While the in vitro results are compelling, the paper acknowledges that further in vivo experiments are needed to fully validate the association of high TKT expression with lymphatic metastasis, advanced TNM stage, and poor survival.
  • Mechanistic Details: The study proposes that TKT might exert its pro-tumor effect by activating the Notch signaling pathway through ROS, but further experiments are required to elucidate the precise molecular mechanisms.
  • Therapeutic Development: The findings highlight TKT as a potential therapeutic target, but this would necessitate the development of specific and effective TKT inhibitors for clinical use.
  • Broader Validation: While the study used multiple datasets and cell lines, validating these findings in a larger and more diverse patient cohort would strengthen the conclusions.

Summary updated

Abstract

Colorectal cancer (CRC) remains a heavy health burden worldwide. Transketolase (TKT) is a crucial enzyme in the non-oxidative phase of the Pentose Phosphate Pathway (PPP), and is up-regulated in multiple cancer types. However, the role of TKT in the prognosis of CRC remains unclear. We aimed to explore whether TKT expression is altered in CRC, how TKT is associated with the prognosis of CRC, and whether the regulation of TKT might have an impact on CRC. Differentially expressed genes (DEGs) were identified using bioinformatics analysis. TKT expression was examined in the human colon adenocarcinoma tissue microarray and xenografts. Cell viability, proliferation, migration, and apoptosis assays <i>in vitro</i> were applied to evaluate the protumoral effects of TKT on CRC. TKT was found to be a risk factor for the poor prognosis of CRC by bioinformatics analysis among the DEGs. TKT was significantly up-regulated in colon adenocarcinoma tissues compared with normal colon tissues in patients. Moreover, similar results were found in HCT116 and RKO human colon adenocarcinoma xenografts in nude mice. TKT expression was positively associated with advanced TNM stage, positive lymph nodes, and poor 5 or 10-year overall survival of CRC patients. <i>In vitro</i>, inhibition of TKT reduced cell viability, proliferation, and migration, and induced cell apoptosis. In addition, inhibition of TKT decreased the protein levels of NICD and Hes1. In conclusion, high TKT expression was associated with the poor prognosis of CRC patients. The protumoral effects of downregulating TKT may be realized by suppressing the Notch signaling pathway. TKT may be a new prognostic biomarker and therapeutic target for CRC.
BibTeX
@inproceedings{zhang2022inhibition,
  author = {Linhao Zhang and Zhiyin Huang and Qiuyu Cai and Chong Zhao and Yang Xiao and Xin Quan and Chengwei Tang and Jinhang Gao},
  title = {{Inhibition of Transketolase Improves the Prognosis of Colorectal Cancer}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2022.837143},
}
Figure